Show simple item record

dc.contributorGEMMAC (Grup per l’estudi del mieloma i l’amiloïdosi de Catalunya)
dc.contributor.authorGranell, Miquel
dc.contributor.authorCalvo, Xavier
dc.contributor.authorGarcia-Guiñón, Antoni
dc.contributor.authorEscoda, Lourdes
dc.contributor.authorAbella, Eugènia
dc.contributor.authorMartínez, Clara Mª
dc.contributor.authorTeixidó, Montserrat
dc.contributor.authorGimenez, Mª Teresa
dc.contributor.authorSenín, Alicia
dc.contributor.authorSanz, Patricia
dc.contributor.authorCampoy, Desirée
dc.contributor.authorVicent, Ana
dc.contributor.authorArenillas, Leonor
dc.contributor.authorRosiñol, Laura
dc.contributor.authorSierra, Jorge
dc.contributor.authorBladé, Joan
dc.contributor.authorFernández de Larrea, Carlos
dc.date.accessioned2021-03-16T11:34:27Z
dc.date.available2021-03-16T11:34:27Z
dc.date.issued2017
dc.identifier.issn0390-6078
dc.identifier.urihttp://hdl.handle.net/10459.1/70757
dc.description.abstractThe presence of circulating plasma cells in patients with multiple myeloma is considered a marker for highly proliferative disease. In the study herein, the impact of circulating plasma cells assessed by cytology on survival of patients with multiple myeloma was analyzed. Wright-Giemsa stained peripheral blood smears of 482 patients with newly diagnosed myeloma or plasma cell leukemia were reviewed and patients were classified into 4 categories according to the percentage of circulating plasma cells: 0%, 1–4%, 5–20%, and plasma cell leukemia with the following frequencies: 382 (79.2%), 83 (17.2%), 12 (2.5%) and 5 (1.0%), respectively. Median overall survival according to the circulating plasma cells group was 47, 50, 6 and 14 months, respectively. At multivariate analysis, the presence of 5 to 20% circulating plasma cells was associated with a worse overall survival (relative risk 4.9, 95% CI 2.6–9.3) independently of age, creatinine, the Durie-Salmon system stage and the International Staging System (ISS) stage. Patients with ≥5% circulating plasma cells had lower platelet counts (median 86×109/L vs. 214×109/L, P<0.0001) and higher bone marrow plasma cells (median 53% vs. 36%, P=0.004). The presence of ≥5% circulating plasma cells in patients with multiple myeloma has a similar adverse prognostic impact as plasma cell leukemia.ca_ES
dc.description.sponsorshiphis study was supported in part by grants AGAUR 2014SGR-1281 and 2014SGR-552 (Generalitat de Catalunya), and RD12/0036/0071, RD12/0036/0046 and PI16/00423 (Instituto de Salud Carlos III) and Fondo Europeo de Desarrollo Regional (FEDER) as well as a grant from the Cellex Research Foundation, Barcelona, Spain.ca_ES
dc.language.isoengca_ES
dc.publisherFerrata Storti Foundationca_ES
dc.publisherEuropean Hematology Associationca_ES
dc.relation.isformatofReproducció del document publicat a https://doi.org/10.3324/haematol.2016.158303ca_ES
dc.relation.ispartofHaematologica, 2017, vol. 102, núm. 6, p. 1099-1104ca_ES
dc.rightscc-by-nc (c) Ferrata Storti Foundation, 2017ca_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subject.otherMieloma múltipleca_ES
dc.titlePrognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definitionca_ES
dc.typeinfo:eu-repo/semantics/articleca_ES
dc.type.versioninfo:eu-repo/semantics/publishedVersionca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_ES
dc.identifier.doihttps://doi.org/10.3324/haematol.2016.158303


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

cc-by-nc (c) Ferrata Storti Foundation, 2017
Except where otherwise noted, this item's license is described as cc-by-nc (c) Ferrata Storti Foundation, 2017